⭐#4: Proteolysis Targeting Chimeras for BTK Efficiently Inhibit #BCell Receptor Signaling and Can Overcome Ibrutinib Resistance in #CLL Cells 👨⚕️👩⚕️ Arbel YS, Katz B et al 👉 https://t.co/wczGS19hZ8 @SacklerMed @SouraskyMedCtr @WeizmannScience #Cell
RT @KRHornberger: Another salvo in the BTK degrader fray. This one argues for the superiority of reversible non-covalent degraders. Fairly…
Another salvo in the BTK degrader fray. This one argues for the superiority of reversible non-covalent degraders. Fairly comprehensive look in many CLL patient samples, including those with ibrutinib-resistant C481 mutations. https://t.co/ZeCjORhI9p
Proteolysis Targeting Chimeras for BTK Efficiently Inhibit B-Cell Receptor Signaling and Can Overcome Ibrutinib Resistance in CLL Cells https://t.co/cZSCGTi3G5